{Reference Type}: Journal Article
{Title}: Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH).
{Author}: Gidari A;Benedetti S;Tordi S;Zoffoli A;Altobelli D;Schiaroli E;De Socio GV;Francisci D;
{Journal}: Infect Dis Rep
{Volume}: 15
{Issue}: 6
{Year}: 2023 Dec 11
暂无{DOI}: 10.3390/idr15060069
{Abstract}: <B>BACKGROUND: </B>Bictegravir (BIC), a recently introduced integrase inhibitor, is available in a single tablet regimen with tenofovir alafenamide (TAF) and emtricitabine (FTC) (BIC-STR). This study aimed to describe a real-life experience with BIC-STR.<BR><B>METHODS: </B>We retrospectively analyzed the data of people living with HIV (PLWH) on antiretroviral therapy (ART) with BIC-STR followed by the Clinic of Infectious Diseases of Perugia (Perugia, Italy) from September 2019 to February 2023.<BR><B>RESULTS: </B>270 PLWH were enrolled with a median follow-up time on BIC-STR of 2.2 years (IQR 1.2-2.7). In the overall population, in treatment-experienced (N = 242), in treatment-naïve (N = 28), and in population with age > 60 years old (N = 86), we observed that CD4 cell count improved in absolute number, percentage and CD4/CD8 ratio, under BIC-STR. Patients with viremia < 50 cp/mL increased in all groups. In the overall population, previous ART with TAF and nadir CD4 cell count favored immunological recovery. In the ART-experienced group, time in therapy with BIC-STR was associated with HIV-RNA undetectability. In the older group, previous opportunistic infection and advanced age were associated with lower CD4 count.<BR><B>CONCLUSIONS: </B>BIC-STR was demonstrated, in real-life, to be a valid option for a switch, such as initial ART.